Celiac disease (CeD) provides an opportunity to study the specificity underlying human Tcell responses to an array of similar epitopes presented by the same human leukocyte antigen-II (HLA-II) molecule. Provided is a TCR which binds the immunodominant HLA-DQ2.5-restricted gluten epitopes, DQ2.5-glia-ω1 (PFPQPEQPF).
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE